Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.6
(0.25%)
SEK 1.6
(0.25%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 22.87 Million | -59.05 Million | -40.11 Million | -32.22 Million | -28 Million | -19.08 Million |
| Net Income | -438 Thousand | -60.17 Million | -25.62 Million | -37.84 Million | -20.24 Million | -22.05 Million |
| Depreciation & Amortization | 447 Thousand | 618 Thousand | 590 Thousand | 697 Thousand | 731 Thousand | 704 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 22.86 Million | 498 Thousand | -15.56 Million | 8.82 Million | -7.19 Million | 2.42 Million |
| Other non-cash items | 1.42 Million | 486 Thousand | 488 Thousand | -3.89 Million | -1.29 Million | -157 Thousand |
| Investing Cash Flow | -2.45 Million | - | -2.7 Million | - | -389 Thousand | -11.07 Million |
| Investments in PPE | -2.45 Million | - | -2.7 Million | - | -93 Thousand | -11.07 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -296 Thousand | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -296 Thousand | - |
| Financing Cash Flow | 24 Thousand | 17.9 Million | 86.39 Million | 50.91 Million | 22.08 Million | 43.37 Million |
| Debt repayment | - | - | -10 Million | -10 Million | -12 Million | -12 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2000.00 | 17.9 Million | 88.8 Million | 48.93 Million | 36.24 Million | 37.87 Million |
| Other Financing Activities | 24 Thousand | 17.9 Million | 7.59 Million | 11.98 Million | -2.16 Million | 5.49 Million |
| Accounts receivables | -2.54 Million | -93 Thousand | -96 Thousand | 3.8 Million | -5.37 Million | -221 Thousand |
| Accounts payables | 2.02 Million | 843 Thousand | -431 Thousand | 846 Thousand | -2.11 Million | 1.31 Million |
| Inventory | 1.00 | - | - | - | - | - |
| Other working capital | 23.38 Million | -252 Thousand | -15.04 Million | 4.17 Million | 296 Thousand | 1.33 Million |
| Cash at beginning of period | 29.49 Million | 70.64 Million | 27.07 Million | 8.38 Million | 14.69 Million | 1.47 Million |
| Cash at end of period | 49.93 Million | 29.49 Million | 70.64 Million | 27.07 Million | 8.38 Million | 14.69 Million |
| Capital Expenditure | -2.45 Million | - | -2.7 Million | - | -93 Thousand | -11.07 Million |
| Effect of forex changes on cash | - | - | - | - | - | -1000.00 |
| Net cash flow / Change in cash | 20.44 Million | -41.15 Million | 43.56 Million | 18.69 Million | -6.31 Million | 13.21 Million |
| Free Cash Flow | 20.41 Million | -59.05 Million | -42.82 Million | -32.22 Million | -28.09 Million | -30.15 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.64 Million | -3.07 Million | -5.04 Million | -438 Thousand | 28.43 Million | -11.83 Million |
| Depreciation & Amortization | 334 Thousand | 257 Thousand | 90 Thousand | 447 Thousand | 84 Thousand | 124 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 1.79 Million | -6.47 Million | 2.26 Million | 22.86 Million | 10.86 Million | -158 Thousand |
| Other non-cash items | 489 Thousand | -257 Thousand | 967 Thousand | 1.42 Million | 178 Thousand | 109 Thousand |
| Investing Cash Flow | 1000.00 | -756 Thousand | -2.45 Million | -2.45 Million | - | - |
| Investments in PPE | 1000.00 | -756 Thousand | -2.45 Million | -2.45 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -225 Thousand | - | - | 24 Thousand | - | 24 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -225 Thousand | - | - | - | - | - |
| Common Stock Issuance | - | - | -22 Thousand | 2000.00 | - | 24 Thousand |
| Other Financing Activities | -225 Thousand | - | 22 Thousand | 24 Thousand | - | 24 Thousand |
| Accounts receivables | -221 Thousand | 509 Thousand | -1.39 Million | -2.54 Million | -1.14 Million | -895 Thousand |
| Accounts payables | 400 Thousand | 262 Thousand | 606 Thousand | 2.02 Million | 2.68 Million | 108 Thousand |
| Inventory | - | - | - | 1.00 | 1000.00 | 1000.00 |
| Other working capital | 1.61 Million | -7.24 Million | 3.05 Million | 23.38 Million | 9.32 Million | 628 Thousand |
| Cash at beginning of period | 39.89 Million | 49.93 Million | 55.07 Million | 29.49 Million | 15.5 Million | 27.24 Million |
| Cash at end of period | 36 Million | 39.89 Million | 49.93 Million | 49.93 Million | 55.07 Million | 15.5 Million |
| Capital Expenditure | 1000.00 | -756 Thousand | -2.45 Million | -2.45 Million | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -3.88 Million | -10.04 Million | -5.13 Million | 20.44 Million | 39.56 Million | -11.74 Million |
| Free Cash Flow | -3.66 Million | -10.04 Million | -5.13 Million | 20.41 Million | 39.56 Million | -11.76 Million |
UGPA3
BLLB
DNET
ALL
DLICY
300463